Thalidomide and lenalidomide: Mechanism-based potential drug combinations

References

• Little R F, Wyvill K M, Pluda J M, Welles L, Marshall V, Figg W D, et al. Activity of thalidomide in AIDS-related Kaposi's sarcoma. J Clin Oncol 2000; 18: 2593–2602
   PubMed Web of Science ®Google Scholar
• Eisen T, Boshoff C, Mak I, Sapunar F, Vaughan M M, Pyle L, et al. Continuous low dose thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer 2000; 82: 812–817
   PubMed Web of Science ®Google Scholar
• Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565–1571
   PubMed Web of Science ®Google Scholar
• Raje N, Anderson K. Thalidomide – a revival story. N Engl J Med 1999; 341: 1606–1609
   PubMed Web of Science ®Google Scholar
• Lenz W. A short history of thalidomide embryopathy. Teratology 1988; 38: 203–215
   PubMedGoogle Scholar
• Bartlett J B, Dredge K, Dalgleish A G. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 2004; 4: 314–322
   PubMed Web of Science ®Google Scholar
• Sampaio E P, Kaplan G, Miranda A, Nery J A, Miguel C P, Viana S M, et al. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J Infect Dis 1993; 168: 408–414
   PubMed Web of Science ®Google Scholar
• Gutierrez-Rodriguez O, Thalidomide. A promising new treatment for rheumatoid arthritis. Arthritis Rheum 1984; 27: 1118–1121
   PubMed Web of Science ®Google Scholar
• Hamza M H. Treatment of Behcet's disease with thalidomide. Clin Rheumatol 1986; 5: 365–371
   PubMed Web of Science ®Google Scholar
• Vogelsang G B, Farmer E R, Hess A D, Altamonte V, Beschorner W E, Jabs D A, et al. Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med 1992; 326: 1055–1058
   PubMed Web of Science ®Google Scholar
• Atra E, Sato E I. Treatment of the cutaneous lesions of systemic lupus erythematosus with thalidomide. Clin Exp Rheumatol 1993; 11: 487–493
   PubMed Web of Science ®Google Scholar
• Muller G W, Chen R, Huang S Y, Corral L G, Wong L M, Patterson R T, et al. Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production. Bioorg Med Chem Lett 1999; 9: 1625–1630
   PubMed Web of Science ®Google Scholar
• , et al. New treatment for myelodysplastic syndrome. FDA Consum 2006; 40: 4
   Google Scholar
• Schey S A, Fields P, Bartlett J B, Clarke I A, Ashan G, Knight R D, et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol 2004; 22: 3269–3276
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bringhen S, Caravita T, Merla E, Capparella V, Callea V, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006; 367: 825–831
   PubMed Web of Science ®Google Scholar
• Palumbo A, Falco P, Corradini P, Crippa C, Di Raimondo F, Falcone A, et al. Oral melphalan, prednisone and lenalidomide for elderly newly diagnosed myeloma patients. Haematologica 2007; 92(Suppl 1)148
   PubMed Web of Science ®Google Scholar
• D'Amato R J, Loughnan M S, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994; 91: 4082–4085
   PubMed Web of Science ®Google Scholar
• Hideshima T, Chauhan D, Shima Y, Raje N, Davies F E, Tai Y T, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000; 96: 2943–2950
   PubMed Web of Science ®Google Scholar
• Mitsiades N, Mitsiades C S, Poulaki V, Chauhan D, Richardson P G, Hideshima T, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002; 99: 4525–4530
   PubMed Web of Science ®Google Scholar
• Chauhan B K, Reed N A, Zhang W, Duncan M K, Kilimann M W, Cvekl A. Identification of genes downstream of Pax6 in the mouse lens using cDNA microarrays. J Biol Chem 2002; 277: 11539–11548
   PubMed Web of Science ®Google Scholar
• Chauhan D, Hideshima T, Rosen S, Reed J C, Kharbanda S, Anderson K C. Apaf-1/cytochrome c-independent and Smac-dependent induction of apoptosis in multiple myeloma (MM) cells. J Biol Chem 2001; 276: 24453–24456
   PubMed Web of Science ®Google Scholar
• Rajkumar S V, Jacobus S, Callander N, Fonseca R, Vesole D, Williams M, et al. Phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol ASCO Ann Meeting Proc Part I 2007; 25(June 20 Supplement), LBA8025
   Google Scholar
• Mitsiades N, Mitsiades C S, Poulaki V, Anderson K C, Treon S P. Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells. Blood 2002; 99: 2162–2171
   PubMed Web of Science ®Google Scholar
• Tolcher A W, Mita M, Meropol N J, von Mehren M, Patnaik A, Padavic K, et al. Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J Clin Oncol 2007; 25: 1390–1395
   PubMed Web of Science ®Google Scholar
• Raje N, Kumar S, Hideshima T, Ishitsuka K, Chauhan D, Mitsiades C, et al. Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Blood 2004; 104: 4188–4193
   PubMed Web of Science ®Google Scholar
• Jakubowiak A, Richardson P, Zimmerman T, Alsina M, Lonial S, Kendall T, et al. A multicenter phase I trial of perifosine (KRX-0401) in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma: preliminary results. Multiple myeloma research consortium (MMRC) trial Haematologica 2007; 92(Suppl 2), abstract no. PO-606
   Google Scholar
• Hideshima T, Mitsiades C, Tonon G, Richardson P G, Anderson K C. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 2007; 7: 585–598
   PubMed Web of Science ®Google Scholar
• Damiano J S, Cress A E, Hazlehurst L A, Shtil A A, Dalton W S. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 1999; 93: 1658–1667
   PubMed Web of Science ®Google Scholar
• Landowski T H, Olashaw N E, Agrawal D, Dalton W S. Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-kappa B (RelB/p50) in myeloma cells. Oncogene 2003; 22: 2417–2421
   PubMed Web of Science ®Google Scholar
• Lin Y C, Shun C T, Wu M S, Chen C C. A novel anticancer effect of thalidomide: inhibition of intercellular adhesion molecule-1-mediated cell invasion and metastasis through suppression of nuclear factor-kappaB. Clin Cancer Res 2006; 12: 7165–7173
   PubMed Web of Science ®Google Scholar
• Gupta D, Treon S P, Shima Y, Hideshima T, Podar K, Tai Y T, et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 2001; 15: 1950–1961
   PubMed Web of Science ®Google Scholar
• Morgan G J, Schey S A, Wu P, Srikanth M, Phekoo K J, Jenner M, et al. Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients. Br J Haematol 2007; 137: 268–269
   PubMed Web of Science ®Google Scholar
• Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 1995; 333: 1757–1763
   PubMed Web of Science ®Google Scholar
• Weidner N, Semple J P, Welch W R, Folkman J. Tumor angiogenesis and metastasis–correlation in invasive breast carcinoma. N Engl J Med 1991; 324: 1–8
   PubMed Web of Science ®Google Scholar
• Meitar D, Crawford S E, Rademaker A W, Cohn S L. Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma. J Clin Oncol 1996; 14: 405–414
   PubMed Web of Science ®Google Scholar
• Ribatti D, Vacca A, Nico B, Fanelli M, Roncali L, Dammacco F. Angiogenesis spectrum in the stroma of B-cell non-Hodgkin's lymphomas. An immunohistochemical and ultrastructural study. Eur J Haematol 1996; 56: 45–53
   PubMed Web of Science ®Google Scholar
• Aguayo A, Kantarjian H, Manshouri T, Gidel C, Estey E, Thomas D, et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 2000; 96: 2240–2245
   PubMed Web of Science ®Google Scholar
• Rajkumar S V, Leong T, Roche P C, Fonseca R, Dispenzieri A, Lacy M Q, et al. Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res 2000; 6: 3111–3116
   PubMed Web of Science ®Google Scholar
• Dredge K, Marriott J B, Macdonald C D, Man H W, Chen R, Muller G W, et al. Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer 2002; 87: 1166–1172
   PubMed Web of Science ®Google Scholar
• Podar K, Tonon G, Sattler M, Tai Y T, Legouill S, Yasui H, et al. The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proc Natl Acad Sci USA 2006; 103: 19478–19483
   PubMed Web of Science ®Google Scholar
• Abe M, Hiura K, Wilde J, Moriyama K, Hashimoto T, Ozaki S, et al. Role for macrophage inflammatory protein (MIP)- 1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma. Blood 2002; 100: 2195–2202
   PubMed Web of Science ®Google Scholar
• Sezer O, Heider U, Jakob C, Zavrski I, Eucker J, Possinger K, et al. Immunocytochemistry reveals RANKL expression of myeloma cells. Blood 2002; 99: 4646–4647
   PubMed Web of Science ®Google Scholar
• Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003; 349: 2483–2494
   PubMed Web of Science ®Google Scholar
• Yaccoby S, Ling W, Zhan F, Walker R, Barlogie B, Shaughnessy J D, Jr. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 2007; 109: 2106–2111
   PubMed Web of Science ®Google Scholar
• Abe M, Hiura K, Wilde J, Shioyasono A, Moriyama K, Hashimoto T, et al. Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood 2004; 104: 2484–2491
   PubMed Web of Science ®Google Scholar
• Roodman G D. New potential targets for treating myeloma bone disease. Clin Cancer Res 2006; 12(20 Part 2)6270s–6273s
   PubMed Web of Science ®Google Scholar
• Terpos E, Dimopoulos M A, Sezer O. The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma. Leukemia 2007; 21: 1875–1884
   Google Scholar
• Anderson G, Gries M, Kurihara N, Honjo T, Anderson J, Donnenberg V, et al. Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. Blood 2006; 107: 3098–3105
   PubMed Web of Science ®Google Scholar
• Iris Breitkreutz S V, Raab M S, Tai Y-T, Raje N, Hideshima T, Chauhan D, et al. Lenalidomide and bortezomib inhibit osteoclast differentiation and activation in multiple myeloma: clinical implications. Blood 2006; 108: 3485
   Google Scholar
• Giuliani N, Morandi F, Tagliaferri S, Lazzaretti M, Bonomini S, Crugnola M, et al. The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood 2007; 110: 334–338
   PubMed Web of Science ®Google Scholar
• Richardson P G, Jagannathan S, Raje N, Ghobrial I, Schlossman R L, Mazumder A, et al. Phase 2 study of rev/vel/dex in relapsed/refractory mm. Haematologica 2007; 92(Suppl 2), PO-660
   PubMed Web of Science ®Google Scholar
• Moreira A L, Sampaio E P, Zmuidzinas A, Frindt P, Smith K A, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 1993; 177: 1675–1680
   PubMed Web of Science ®Google Scholar
• Wettstein A R, Meagher A P. Thalidomide in Crohn's disease. Lancet 1997; 350: 1445–1446
   PubMed Web of Science ®Google Scholar
• Corral L G, Muller G W, Moreira A L, Chen Y, Wu M, Stirling D, et al. Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity. Mol Med 1996; 2: 506–515
   PubMed Web of Science ®Google Scholar
• Corral L G, Haslett P A, Muller G W, Chen R, Wong L M, Ocampo C J, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 1999; 163: 380–386
   PubMed Web of Science ®Google Scholar
• LeBlanc R, Hideshima T, Catley L P, Shringarpure R, Burger R, Mitsiades N, et al. Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood 2004; 103: 1787–1790
   PubMed Web of Science ®Google Scholar
• Marriott J B, Clarke I A, Dredge K, Muller G, Stirling D, Dalgleish A G. Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells. Clin Exp Immunol 2002; 130: 75–84
   PubMed Web of Science ®Google Scholar
• Haslett P A, Corral L G, Albert M, Kaplan G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 1998; 187: 1885–1892
   PubMed Web of Science ®Google Scholar
• Schafer P H, Gandhi A K, Loveland M A, Chen R S, Man H W, Schnetkamp P P, et al. Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J Pharmacol Exp Ther 2003; 305: 1222–1232
   PubMed Web of Science ®Google Scholar
• Miura Y, Tsujioka T, Nishimura Y, Sakaguchi H, Maeda M, Hayashi H, et al. TRAIL expression up-regulated by interferon-gamma via phosphorylation of STAT1 induces myeloma cell death. Anticancer Res 2006; 26: 4115–4124
   PubMed Web of Science ®Google Scholar
• Haslett P A, Hanekom W A, Muller G, Kaplan G. Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8+ T cells in vitro. J Infect Dis 2003; 187: 946–955
   PubMed Web of Science ®Google Scholar
• Geitz H, Handt S, Zwingenberger K. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology 1996; 31: 213–221
   PubMed Web of Science ®Google Scholar
• Davies F E, Raje N, Hideshima T, Lentzsch S, Young G, Tai Y T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001; 98: 210–216
   PubMed Web of Science ®Google Scholar
• Tai Y T, Li X F, Catley L, Coffey R, Breitkreutz I, Bae J, et al. Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications. Cancer Res 2005; 65: 11712–11720
   PubMed Web of Science ®Google Scholar
• Jin S H, Kim T I, Yang K M, Kim W H. Thalidomide destabilizes cyclooxygenase-2 mRNA by inhibiting p38 mitogen-activated protein kinase and cytoplasmic shuttling of HuR. Eur J Pharmacol 2007; 558: 14–20
   PubMed Web of Science ®Google Scholar
• Ladetto M, Vallet S, Trojan A, Dell'Aquila M, Monitillo L, Rosato R, et al. Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome. Blood 2005; 105: 4784–4791
   PubMed Web of Science ®Google Scholar
• Prince H M, Mileshkin L, Roberts A, Ganju V, Underhill C, Catalano J, et al. A multicenter phase II trial of thalidomide and celecoxib for patients with relapsed and refractory multiple myeloma. Clin Cancer Res 2005; 11: 5504–5514
   PubMed Web of Science ®Google Scholar
• Villalona-Calero M, Schaaf L, Phillips G, Otterson G, Panico K, Duan W, et al. Thalidomide and celecoxib as potential modulators of irinotecan's activity in cancer patients. Cancer Chemother Pharmacol 2007; 59: 23–33
   PubMed Web of Science ®Google Scholar
• Lentzsch S, LeBlanc R, Podar K, Davies F, Lin B, Hideshima T, et al. Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo. Leukemia 2003; 17: 41–44
   PubMed Web of Science ®Google Scholar
• Dredge K, Marriott J B, Todryk S M, Muller G W, Chen R, Stirling D I, et al. Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity. J Immunol 2002; 168: 4914–4919
   PubMed Web of Science ®Google Scholar
• List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006; 355: 1456–1465
   PubMed Web of Science ®Google Scholar
• Mileshkin L, Stark R, Day B, Seymour J F, Zeldis J B, Prince H M. Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol 2006; 24: 4507–4514
   PubMed Web of Science ®Google Scholar
• Dunkley S, Gaudry L. Thalidomide causes platelet activation, which can be abrogated by aspirin. J Thromb Haemost 2007; 5: 1323–1325
   PubMed Web of Science ®Google Scholar
• Hirsh J. Risk of thrombosis with lenalidomide and its prevention with aspirin. Chest 2007; 131: 275–277
   PubMed Web of Science ®Google Scholar
• Breitkreutz I, Lokhorst H M, Raab M S, Holt B, Cremer F W, Herrmann D, et al. Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield. Leukemia 2007; 21: 1294–1299
   PubMed Web of Science ®Google Scholar
• Kumar S, Dispenzieri A, Lacy M Q, Hayman S R, Buadi F K, Gastineau D A, et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia 2007; 21: 2035–2042
   PubMed Web of Science ®Google Scholar
• Paul G, Richardson S J, Avigan D E, Alsina M, Schlossman R L, Mazumder A, et al. Lenalidomide plus bortezomib (Rev-Vel) in relapsed and/or refractory multiple myeloma (MM): final results of a multicenter phase 1 trial. Blood 2006; 108: 405
   PubMed Web of Science ®Google Scholar
• Siddhartha Mukherjee N R, Patel C, Vallet S, Aronson J, Chhetri S, Mitsiades C, et al. Scadden bortezomib induces proliferation of mesenchymal progenitor cells and promotes differentiation towards osteoblastic lineage. Blood 2006; 108: 88
   PubMed Web of Science ®Google Scholar